Effects of Feixinning Capsules on BODE Index,CRP and Quality of Life in AECOPD Patients with Right Heart Failure

[Objectives]To investigate the therapeutic effect of Feixinning Capsules on acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated with right heart failure.[Methods]A total of 60 cases of AECOPD patients with right heart failure and phlegm-heat syndrome were randomly selected as the study subjects,and were divided into the Feixinning group(n=30)and the control group(n=30).The Feixinning group was treated with Feixinning Capsules combined with conventional western medicine,and the control group was treated with conventional western medicine.The pulmonary function,CRP,CAT score,BODE index item index,and EQ-5D index were compared between the two groups before and after treatment.[Results]After treatment,the pulmonary function,CRP,CAT score,6MWD,mMRC,BODE score and EQ-5D index in the Feixinning group were significantly improved compared with the control group(P<0.05),and there was no statistical difference in the change of BMI index(P>0.05).[Conclusions]Feixinning Capsules can effectively improve the clinical symptoms and quality of life of patients with AECOPD complicated with right heart failure and phlegm-heat syndrome.

自拟中药方肺心安联合西药治疗气阴两虚型慢性阻塞性肺疾病稳定期30例疗效观察

目的 观察肺心安治疗气阴两虚型慢性阻塞性肺疾病(COPD)稳定期的临床疗效。方法 选择2019年1月—2020年12月首都医科大学附属北京朝阳医院中医科门诊及病房收治的气阴两虚型COPD稳定期患者60例,肺功能Ⅱ~Ⅲ级,随机分为对照组与试验组,每组30例。对照组予西医基础治疗,试验组在西药基础上加肺心安,1袋/次,2次/d,12周为1个疗程,随访6个月。比较2组疗效,治疗前后中医证候积分、COPD评估测试(CAT)评分、改良英国医学研究学会呼吸困难指数量表(mMRC)评分、急性加重次数、实验室指标及不良反应。结果 试验组总有效率96.67%,高于对照组83.33%,差异有统计学意义(P<0.05)。治疗后,2组中医证候总积分、CAT评分、mMRC评分、血清缺氧诱导因子(HIF-1α)水平均较治疗前降低(P<0.05),血清1,25-二羟维生素D[1,25 (OH)D]水平均较治疗前升高(P<0.05),且试验组以上指标优于对照组,差异有统计学意义(P<0.05)。所有患者治疗后均未见明显不良反应。结论 肺心安联合西医基础治疗气阴两虚型COPD稳定期患者能够提高临床疗效,改善临床症状,减少急性加重次数。